Savara (SVRA)

• Market cap: $1.09B
• 1 day: -2.38%
• 5 days: -3.96%
• 1 month: -14.03%
• 3 months: 0.57%
• 6 months: -5.83%
• Year to date: -5.5%
• 1 year: 107.39%
• 5 years: 336.89%
• 10 years: -78.15%
• Sector: Healthcare
• Industry: Biotechnology

About: Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Employees: 70